FDA Cleared Currus Biologics Drug Trial
The FDA approved an Investigational New Drug application for a novel cancer therapy, CUR-001.
Updated on Sept. 28, 2026 in Biotech
Live Poll
Should medical researchers prioritize developing new therapies for solid tumours?
The U.S. Food and Drug Administration has cleared the Investigational New Drug application for CUR-001, a therapeutic candidate from Currus Biologics. The company will now initiate a Phase 1 clinical trial for patients with mesothelin-positive advanced refractory solid tumours.
Why it matters
The candidate is specifically engineered to navigate the complex microenvironments of solid tumours, which frequently cause CAR T-cell exhaustion and limit therapeutic efficacy. By utilizing the proprietary BEAT platform, this treatment seeks to bypass the biological barriers that have historically hindered cell therapy in solid cancer cases.
CUR-001 integrates a bispecific antibody platform called BEAT with FLAG-tagged autologous anti-mesothelin CAR T-cell therapy. The system works by engaging CAR T-cells and antigen-presenting cells to trigger activation within lymphoid tissue.
The players
Currus Biologics
A biotechnology firm based in Melbourne, Australia, that focuses on developing advanced cell therapies for cancer treatment.
U.S. Food and Drug Administration
The federal agency responsible for regulating food, tobacco products, and pharmaceutical drugs in the United States.
The details
Currus Biologics, headquartered in Melbourne, Australia, will utilize a basket study design to test the treatment in patients battling advanced refractory solid tumours. The company is supported by venture capital firms including Brandon Capital Partners, Main Sequence Ventures, and Uniseed.
Timeline
September 28, 2026: The FDA cleared the Investigational New Drug application for CUR-001.
Early 2027: The first patient in the study is expected to be dosed.
The Tech Race
This development reflects a major shift in the biotech industry as firms move beyond blood cancers to tackle solid tumours, which account for the vast majority of cancer cases. It places Currus Biologics in the ongoing race to solve CAR T-cell exhaustion using specialized bispecific antibody platforms.
For patients suffering from advanced solid tumours, this represents a potential future pathway for treatment as the therapy moves into human clinical trials. While the drug is not yet available, the success of the trial could eventually lead to new options for those who have exhausted standard medical interventions.
The takeaway
The transition of CAR T-cell therapy into the realm of solid tumours marks a significant evolution in personalized medicine. Patients and providers should monitor early clinical trial results to see if these platforms can effectively breach the microenvironment barriers that have limited cell therapies in the past.
What happens next
The Phase 1 basket study is scheduled to begin patient dosing in early 2027.
Further reading
For more information on the latest innovations in cancer research, visit Biotech.
Live Poll
Should medical researchers prioritize developing new therapies for solid tumours?
